Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'- Poll: 62% of Americans would oppose U.S. military action in Greenland
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- German foreign minister backs abandoning EU's unanimity principle
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Computerized Strengthening d: A Survey of \Upgrading Efficiency\ Programming Application
- Explainer-What has happened to the damaged spacecraft at China's space station?
- The Artemis II launch is tonight. Here's how to watch it live.
